Blueprint Medicines Stock Analysis, Valuation (NASDAQ:BPMC)

Add to My Stocks
$62.28 $0.18 (0.29%) BPMC stock closing price Sep 22, 2017 (Closing)
Watch Robo Advisor Video of BPMC Stock Analysis
Blueprint Medicines
Updated on : Sep 22, 2017
previous close
BPMC 62.3 (0%)
S&P 500 2502.2 (0%)
Closing Price On: Sep 22, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-394.1%
Sector Average:
-2.3%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Debt/Equity Ratio
Debt:
7.4M
Debt/Equity Ratio:
 0.02
Compared to the industry
Cash Flow
Operating cash flow:
-$27.5M
Net Income:
-$33.4M
PROS      CONS
Low Debt Burden
Operating Margins
Net Margins
ROE
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
BPMC PS :
94.4
Industry PS :
5.3
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-50.5%
Free Cash Flow Margin:
-471.1%
Double Tap To Exit Full Screen
0:00
/

Blueprint Medicines Stock Analysis

14 5 3

View Blueprint Medicines stock analysis video. This is our analyst opinion covering the buy and sell arguments for BPMC stock.

Blueprint Medicines Corp Stock Rating 1.9/5

Our Blueprint Medicines stock opinion is based on fundamentals of the company. This Blueprint Medicines stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy BPMC stock?

  • With its debt/equity ratio of  0.02, Blueprint Medicines has a lower debt burden when compared to the Medical average.

Should you sell BPMC stock?

  • Over the last twelve months, Blueprint Medicines posted an average operating loss margin of -394.1%.
  • Over the last 12 months, Blueprint Medicines had an average Net loss of -388.9%.
  • The company does not have profits. Hence the PE ratio is meaningless for BPMC stock.
  • The company is trading at a price to sales multiple of 94.4, which is overvalued in comparison to the Medical-Biomed-Genetics industry average multiple of 5.3.
  • A negative ROE of -50.5% indicates that the company is not able to generate profits with the money shareholders have invested.
  • The company has a negative free cash flow margin of -471.1%.

Comments on this video and Blueprint Medicines stock